ACIU AC Immune SA IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1651625 · Reporting currency CHF · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CHF | FY2025*2025-12-31 | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 3.57M | 27.31M | 14.80M | 3.94M | 0 |
| R&D expense | 56.44M | 62.57M | 54.61M | 60.34M | 62.28M |
| SG&A expense | 16.09M | 17.26M | 15.30M | 15.79M | 17.91M |
| Operating income | -69.32M | -52.38M | -53.62M | -70.85M | -79.01M |
| Interest expense | 191,000 | 133,000 | 176,000 | 355,000 | 581,000 |
| Pretax income | -70.45M | -50.91M | -54.22M | -70.74M | -72.99M |
| Income tax | 0 | 3,000 | 10,000 | 13,000 | 3,000 |
| Net income | -70.45M | -50.92M | -54.23M | -70.75M | -73.00M |
| EPS (basic) | -0.70 | -0.51 | -0.64 | -0.85 | -0.97 |
| EPS (diluted) | -0.70 | -0.51 | -0.64 | -0.85 | -0.97 |
| Weighted avg. shares (diluted) | 100.75M | 99.69M | 84.69M | 83.55M | 74.95M |
| Balance sheet | |||||
| Cash & equivalents | 26.80M | 36.27M | 78.49M | 31.59M | 82.22M |
| Short-term investments | 64.62M | 129.21M | 24.55M | 91.00M | 116.00M |
| Receivables | — | 0 | 14.80M | — | — |
| Current assets | 96.72M | 171.99M | 125.15M | 128.09M | 202.63M |
| PP&E, netmay include right-of-use assets (IFRS) | 1.99M | 2.65M | 3.38M | 4.26M | 5.12M |
| Intangibles | 50.42M | 50.42M | 50.42M | 50.42M | 50.42M |
| Total assets | 154.25M | 230.91M | 182.81M | 185.94M | 261.44M |
| Current liabilities | 94.69M | 100.84M | 13.58M | 11.48M | 20.03M |
| Total liabilities | 109.37M | 118.64M | 22.17M | 16.95M | 29.46M |
| Shareholders' equity | 44.88M | 112.27M | 160.64M | 168.99M | 231.98M |
| Cash flow statement | |||||
| Operating cash flow | -69.26M | 65.84M | -60.41M | -73.57M | -65.69M |
| Capital expenditure | 900,000 | 576,000 | 801,000 | 1.24M | 2.63M |
| Free cash flow | -70.16M | 65.27M | -61.21M | -74.81M | -68.32M |
| Investing cash flow | 63.54M | -105.29M | 65.64M | 23.76M | -53.66M |
| Financing cash flow | -1.02M | -1.12M | 43.25M | -1.35M | 40.75M |
| Stock-based compensation | 4.40M | 5.47M | 4.37M | 3.33M | 4.13M |
| Share buybacks | — | — | — | 0 | 0 |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, CHF, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.